We are live on ! Find out more
ACIU icon

AC Immune

45 hedge funds and large institutions have $114M invested in AC Immune in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

419% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $219K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

33% more capital invested

Capital invested by funds: $85.7M → $114M (+$28.3M)

22% more funds holding

Funds holding: 3745 (+8)

0.39% less ownership

Funds ownership: 29.2%28.8% (-0.39%)

50% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 16

Holders
45
Holders Change
+8
Holders Change %
+21.62%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
8
Reduced
16
Closed
6
Calls
$1.14M
Puts
$219K
Net Calls
+$918K
Net Calls Change
+$787K
Name Holding Trade Value Shares
Change
Change in
Stake
Simplex Trading
51
Simplex Trading
Illinois
-$2.1K -635 Closed

ACIU Hedge Fund Activity: Q2 2024 in Review

45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q2 2024, worth a combined $114M — up 33% from $85.7M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ACIU positions and 6 closed out — a net gain of 8 holders — while 8 added to existing stakes and 16 trimmed.

The largest buyer was BVF Inc, adding an estimated $14.1M. The largest seller was Avidity Partners Management, cutting an estimated $12.1M.

  • 45 institutional investors held AC Immune (ACIU) as of Q2 2024, up from 37 in Q1 2024.
  • Funds reported $114M of AC Immune stock for Q2 2024, up 33% quarter-over-quarter.
  • 14 funds opened new AC Immune positions in Q2 2024 and 6 closed out, a net change of +8 holders.
  • The largest AC Immune buyer in Q2 2024 was BVF Inc, an estimated $14.1M added.
  • The largest AC Immune seller in Q2 2024 was Avidity Partners Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2024.